Literature DB >> 22082333

Microvesicles as novel biomarkers and therapeutic targets in transplantation medicine.

F Fleissner1, Y Goerzig, A Haverich, T Thum.   

Abstract

Microvesicles (MVs) including exosomes are emerging new biomarkers and potential regulators of inflammation and immunological processes. Such particles contain proteins and genetic information including DNA and microRNAs that may be of importance for cell/cell communication. However, their role during and after organ transplantation and immunomodulatory effects is only in its beginning of understanding. We here, in brief, introduce generation and biological importance of MVs, describe their (patho)physiological roles and their potential use as future biomarkers and therapeutic agents in transplantation medicine. Circulating MVs may have a great potential to detect possible immune rejections and MV modulation may emerge as a therapeutic approach in organ rejection therapy.
© 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082333     DOI: 10.1111/j.1600-6143.2011.03790.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  29 in total

1.  Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue.

Authors:  Prashanth Vallabhajosyula; Laxminarayana Korutla; Andreas Habertheuer; Ming Yu; Susan Rostami; Chao-Xing Yuan; Sanjana Reddy; Chengyang Liu; Varun Korutla; Brigitte Koeberlein; Jennifer Trofe-Clark; Michael R Rickels; Ali Naji
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

Review 2.  Microparticles: new light shed on the understanding of venous thromboembolism.

Authors:  Lin Zhou; Xiao-long Qi; Ming-xin Xu; Yu Mao; Ming-lin Liu; Hao-ming Song
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

3.  Bone marrow mesenchymal stem cell-derived microvesicles protect rat pheochromocytoma PC12 cells from glutamate-induced injury via a PI3K/Akt dependent pathway.

Authors:  Shan-Shan Lin; Bo Zhu; Zi-Kuan Guo; Guo-Zhi Huang; Zi Wang; Jin Chen; Xiao-Juan Wei; Qi Li
Journal:  Neurochem Res       Date:  2014-04-06       Impact factor: 3.996

4.  Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro.

Authors:  Arsalan Shabbir; Audrey Cox; Luis Rodriguez-Menocal; Marcela Salgado; Evangelos Van Badiavas
Journal:  Stem Cells Dev       Date:  2015-05-20       Impact factor: 3.272

Review 5.  Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers.

Authors:  Crislyn D'Souza-Schorey; James W Clancy
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

6.  Exosomes Function in Pro- and Anti-Angiogenesis.

Authors:  Mara Fernandes Ribeiro; Hongyan Zhu; Ronald W Millard; Guo-Chang Fan
Journal:  Curr Angiogenes       Date:  2013

7.  Donor dendritic cell-derived exosomes promote allograft-targeting immune response.

Authors:  Quan Liu; Darling M Rojas-Canales; Sherrie J Divito; William J Shufesky; Donna Beer Stolz; Geza Erdos; Mara L G Sullivan; Gregory A Gibson; Simon C Watkins; Adriana T Larregina; Adrian E Morelli
Journal:  J Clin Invest       Date:  2016-06-27       Impact factor: 14.808

8.  Circulating extracellular vesicles in cancer diagnosis and monitoring: an appraisal of clinical potential.

Authors:  Dong-Sic Choi; Jaewook Lee; Gyeongyun Go; Yoon-Keun Kim; Yong Song Gho
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

9.  Whether Circulating miRNAs or miRNA-Carriers Serve as Biomarkers for Acute Myocardial Infarction.

Authors:  Hongyan Zhu; Guo-Chang Fan
Journal:  J Biomark Drug Dev       Date:  2012-08-02

Review 10.  Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity.

Authors:  Weifan Yin; Song Ouyang; Yi Li; Bo Xiao; Huan Yang
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.